白喉毒素无毒突变蛋白CRM197的特性和CRM197结合疫苗研究进展  

Characteristics of diphtheria toxin non-toxic mutant protein CRM197 and research progress of CRM197 conjugate vaccines

作　　者：魏明伟[1] 梁祁[1] 潘红星[1] Wei Mingwei;Liang Qi;Pan Hongxing(Vaccine Clinical Evaluation Department,Jiangsu Provincial Center for Disease Control and Prevention,Nanjing 210009,Jiangsu,China)

机构地区：[1]江苏省疾病预防控制中心疫苗临床评价所,江苏南京210009

出　　处：《中国疫苗和免疫》2023年第3期353-364,共12页Chinese Journal of Vaccines and Immunization

摘　　要：多糖蛋白结合疫苗的发展和应用对全球传染病的控制至关重要。白喉毒素无毒突变蛋白197(Cross-reacting material 197,CRM197)作为一种结合疫苗的载体蛋白具有良好的免疫原性、有效性和安全性,广泛应用于细菌、病毒、癌症等多种疫苗研发,与现有疫苗有较少的免疫干扰。本文综述了CRM197的基本特性和近年来CRM197结合疫苗研究进展。Development and use of polysaccharide-protein conjugate vaccines are critical to the control of global infectious diseases.The non-toxic cross-reacting material of diphtheria toxin 197(CRM197)as a carrier protein for conjugated vaccines has good immunogenicity,efficacy/effectiveness,and safety.It has been used in research and development of many vaccines against bacteria,viruses,and cancers,and has less immune interference with existing vaccines.In this paper,we review basic characteristics of CRM197 and research progress of CRM197 conjugate vaccines in recent years.

关 键 词：CRM197载体蛋白 CRM197结合疫苗 白喉类毒素 

分 类 号：R186[医药卫生—流行病学]